Why the study?
Do belatacept-based regimens improve cardiovascular and metabolic risk factors compared to cyclosporine A in kidney transplant recipients?
Population
1,209 kidney transplant recipients
Comparison
Belatacept-based regimens vs Cyclosporine A (CsA)
Design
RCT, randomized
Follow-up
12 months
Authors
Loading...
Supports belatacept preference to improve BP and lipid control in kidney transplant recipients; extends phase 3 RCT evidence versus cyclosporine.
Do belatacept-based regimens improve cardiovascular and metabolic risk factors compared to cyclosporine A in kidney transplant recipients?
Belatacept-based immunosuppression is associated with a more favorable cardiovascular and metabolic risk profile at 12 months compared to cyclosporine A in kidney transplant recipients.
Vanrenterghem et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: